Who are Precedex (Dexmedetomidine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Norepinephrine (Levophed), Nebulized lidocaine and dexmedetomidine, Dexmedetomidine 0.5 microgram/kg, Escitalopram+Mirtazapine, dexmedetomidine 1 µg/kg IV, Catapresan TTS 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/precedex-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Precedex (Dexmedetomidine) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precedex (Dexmedetomidine) (Precedex (Dexmedetomidine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia/Sedation.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia/Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Precedex (Dexmedetomidine) (Precedex (Dexmedetomidine)) — Icahn School of Medicine at Mount Sinai. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Precedex (Dexmedetomidine) TARGET	Precedex (Dexmedetomidine)	Icahn School of Medicine at Mount Sinai	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Nebulized lidocaine and dexmedetomidine	Nebulized lidocaine and dexmedetomidine	Ain Shams University	marketed	Local anesthetic and sedative-analgesic combination	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Dexmedetomidine 0.5 microgram/kg	Dexmedetomidine 0.5 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Escitalopram+Mirtazapine	Escitalopram+Mirtazapine	Ministry of Health & Welfare, Korea	marketed	Antidepressant combination (SSRI + NaSSA)	Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
dexmedetomidine 1 µg/kg IV	dexmedetomidine 1 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Catapresan TTS 2	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Precedex (Dexmedetomidine) — Competitive Intelligence Brief. https://druglandscape.com/ci/precedex-dexmedetomidine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing